{
    "nct_id": "NCT03691714",
    "official_title": "An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",
    "inclusion_criteria": "* Body weight > 30 kg\n* Histologically or cytologically confirmed recurrent or metastatic HNSCC\n* Not considered a candidate for other curative therapy (i.e. surgery/RT)\n* Documented progression of disease after receiving platinum based regimen\n* ECOG performance status 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Nasopharyngeal and salivary gland tumors\n* Prior exposure to both immunotherapy drugs and Cetuximab. Single exposure to either immunotherapy or cetuximab is allowed.",
    "miscellaneous_criteria": ""
}